KPR Mill | Q1FY25 Result Update
Edelweiss
Revenue was flat at INR1,610cr (est. INR1,617cr)
Broker Research reports: All reports
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 Aug 2024 | KPR Mill |
Edelweiss
|
1184.75 | 973.00 | 873.45 (35.64%) | Target met |
Hold
|
||||
| 16 Aug 2024 | Apollo Hospitals |
ICICI Direct
|
6970.00 | 6680.00 | 6686.90 (4.23%) | Target met |
Hold
|
||||
| 16 Aug 2024 | Granules |
Geojit BNP Paribas
|
516.15 | 732.00 | 662.35 (-22.07%) | 41.82 |
Accumulate
|
||||
| 15 Aug 2024 | Apollo Hospitals |
ICICI Securities Limited
|
6970.00 | 6215.00 | 6515.85 (6.97%) | Target met |
Hold
|
In-line quarter; striving to improve margins
ICICI Securities Limited
Apollo Hospitals’ (Apollo) Q1FY25 revenue and EBITDA were in-line with our estimates. Apollo is aiming for a 100bps improvement in its hospital margins driven by a 7% YoY increase.
|
|||
| 15 Aug 2024 | Cello World |
Monarch Networth Capital Limited
|
602.20 | 960.00 | 888.45 (-32.22%) | 59.42 |
Accumulate
|
||||
| 14 Aug 2024 | Britannia Industries |
KRChoksey
|
5520.50 | 5968.00 | 5659.15 (-2.45%) | Target met |
Accumulate
|
Gradual improvement in volumes and margins will lead to healthy earning growth
KRChoksey
For Q1FY25, BRIT’s revenue was INR 42,504 Mn, up 6.0% YoY (+4.4% QoQ), which was in line with our estimates. The sales growth was driven by high-single-digit volume growth.
|
|||
| 14 Aug 2024 | Aurobindo Pharma |
KRChoksey
|
1204.70 | 1591.00 | 1519.70 (-20.73%) | Target met |
Accumulate
|
Stable demand and pricing led to continued revenue growth
KRChoksey
Aurobindo Pharma’s revenue, EBITDA and Adj. PAT was in-line with our estimates.
The injectable and specialty business showed robust performance, particularly in the US, indicating a strong product pipeline. |
|||
| 14 Aug 2024 | Piramal Enterprises |
Motilal Oswal
|
1142.05 | 950.00 | 882.40 (29.43%) | Target met |
Neutral
|
||||
| 14 Aug 2024 | Ratnamani Metals & Tubes |
Sharekhan
|
2880.70 | 3832.00 | 3523.40 (-18.24%) | Target met |
Hold
|
||||
| 14 Aug 2024 | Ipca Laboratories |
Motilal Oswal
|
1457.30 | 1310.00 | 1349.05 (8.02%) | Target met |
Neutral
|
||||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.